In brief
HeartBeam, Inc. has named Bryan Humbarger its chief commercial officer, with the appointment effective Jan. 22, 2026. The company says Humbarger will oversee commercial planning and implementation, including work tied to the limited launch of its HeartBeam System for arrhythmia assessment, a heart attack detection indication, and a 12-lead ECG extended-wear patch monitor. His responsibilities will also include growing engagement with cardiology partners to assess performance in real-world use and develop reference sites intended to support broader adoption. HeartBeam describes itself as a medical technology company focused on cardiac condition detection and monitoring. The company says its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025.
Key takeaways
- Bryan Humbarger was appointed chief commercial officer, effective Jan. 22, 2026.
- He will lead commercial strategy and execution across company growth initiatives.
- His work includes the HeartBeam System launch and outreach to cardiology partners.
- HeartBeam reports FDA clearances for arrhythmia assessment and 12-lead ECG synthesis software.
HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication and a 12-lead ECG extended wear patch monitor, while expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.
To view the full press release, visit https://ibn.fm/9YzeT
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025*.
*Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What will Bryan Humbarger do as HeartBeam's chief commercial officer?
Humbarger is set to oversee the company’s commercial planning and its implementation. The release says his work will include supporting an initial, limited market introduction of the cleared arrhythmia-assessment system, advancing initiatives related to a heart-attack detection indication and an extended-wear ECG patch, and developing relationships with cardiology partners to assess performance in routine use and create reference sites.
What is the HeartBeam System designed to assess?
The release describes the system as cleared for arrhythmia assessment and says the company is pursuing a heart-attack detection indication. It also identifies a 12-lead ECG extended-wear patch monitor among the commercial initiatives. The notice does not provide detailed operating instructions or clinical performance results for these offerings.
How does HeartBeam's ECG technology collect and present cardiac signals?
The company says its cable-free technology gathers ECG signals from three directions that are not in the same plane, then uses software to produce a 12-lead ECG. The platform is intended for portable devices used outside medical facilities, where clinicians could review cardiac trends and acute conditions and guide patients toward appropriate care.
Earlier from HeartBeam, Inc.
- FDA Clearance for HeartBeam (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup
- HeartBeam (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation
- HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
- HeartBeam (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
